Pharmaceutical Executive January 13, 2026
Key Takeaways
- Moderna is focusing on cost reduction, financial stabilization, and expanding its product portfolio post-pandemic.
- The company reported $1.9 billion in revenue for 2025, exceeding expectations, and achieved significant cost savings.
- Moderna aims to establish a seasonal respiratory vaccine franchise to fund oncology and rare disease investments.
- Key developments include regulatory progress on flu vaccines and advancements in oncology and rare disease pipelines.
- The company anticipates nearly 10% revenue growth in 2026, with continued cost reductions and a target of cash breakeven by 2028.
Moderna CEO Stéphane Bancel positions 2026 as a catalyst-rich year driven by new vaccine launches, late-stage oncology data, and continued cost discipline.
Speaking at the first day of the 44th Annual J.P. Morgan...
Today's Sponsors
Today's Sponsor